Q BioMed Inc., a biomedical acceleration and development company, focuses on licensing, acquiring, and providing resources to life sciences and healthcare companies. The company offers Strontium Chloride Sr-89 and Metastron, a radiopharmaceutical therapeutic for the treatment of metastatic bone cancer pain. It is also developing Man-01, that is used for the treatment of primary open angle glaucoma; QBM-001 for rare pediatric non-verbal autism spectrum disorder; and Uttroside-B, a novel chemotherapeutic for liver cancer. Q BioMed Inc. has a partnership with Mannin Research Inc. for the development of therapeutic drugs to treat acute respiratory distress syndrome, glaucoma, kidney diseases, and others. The company was formerly known as ISMO Tech Solutions, Inc. and changed its name to Q BioMed Inc. in July 2015. Q BioMed Inc. was incorporated in 2013 and is based in New York, New York.
| 0.0005 | |
| 0.0005 | |
| - | |
| 0.0005 | |
| 0.0005 | |
| 0.0001-0.0036 | |
| 72 547 | |
| 145 M | |
| 209 K | |
| 82.638 |
No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.
AUSTIN, Texas, Sept. 22, 2020 (GLOBE NEWSWIRE) -- SmallCapVoice.com, Inc. (“SCV”) today announces the availability of a new interview with Q BioMed Inc. (“the Company”) (OTCQB: QBIO), a comm...
AUSTIN, Texas, July 09, 2020 (GLOBE NEWSWIRE) -- SmallCapVoice.com, Inc. (“SCV”) today announces the availability of a new interview with Q BioMed Inc. (“the Company”) (OTCQB: QBIO), a comme...
Our 24/7 support would be happy to assist you via chat or email:
support@eodhistoricaldata.comVisit also:
